Flex Pharma

MedPharmPharmaceuticalsUnited Kingdom

65% match

MedPharm is a privately held pharmaceutical development company with its global headquarters in Guildford, United Kingdom, partnering with clients worldwide to design topical, transdermal, and complex drug products.

OREXO AB OREXO0H19 · PharmaceuticalsUnited Kingdom

64% matchPublic

Orexo AB is a pharmaceutical company that specializes in developing innovative drug delivery technologies, notably its powder-based AmorphOX platform. The company advances proprietary and partnered pharmaceutical products, including treatments, vaccines, and nasal delivery formulations, serving patients and healthcare partners globally.

INTREPID Robotics, Inc.Pharmaceuticals & BiotechnologyUnited States

63% matchPrivate

INTREPID Robotics, Inc. provides an AI-driven drug formulation platform designed to accelerate therapeutic development for pharmaceutical and biotechnology companies. The company combines artificial intelligence, automation, and formulation expertise to convert candidate molecules into optimized, manufacturable drug formulations.

DENOVO SCIENCES, INC.Biotechnology & PharmaceuticalsUnited States

62% matchPrivate

Denovo Sciences Inc. is an AI-driven drug discovery company developing proprietary technologies and automated systems for early-stage small-molecule discovery and single-cell analysis. The company has collaborated with international partners to address unmet medical needs.

CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company’s technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered dissolvable strip. The company is based in Tampa, Florida.

Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.